- Home
- STEM vs BCAB Comparison
STEM vs BCAB Comparison
Compare STEM & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEM
- BCAB
- Stock Information
- Founded
- STEM 2009
- BCAB 2007
- Country
- STEM United States
- BCAB United States
- Employees
- STEM N/A
- BCAB N/A
- Industry
- STEM Computer Software: Prepackaged Software
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- STEM Technology
- BCAB Health Care
- Exchange
- STEM Nasdaq
- BCAB Nasdaq
- Market Cap
- STEM 100.2M
- BCAB 91.4M
- IPO Year
- STEM N/A
- BCAB 2020
- Fundamental
- Price
- STEM $0.57
- BCAB $1.85
- Analyst Decision
- STEM Hold
- BCAB Strong Buy
- Analyst Count
- STEM 12
- BCAB 2
- Target Price
- STEM $2.72
- BCAB $6.00
- AVG Volume (30 Days)
- STEM 7.4M
- BCAB 1.9M
- Earning Date
- STEM 10-30-2024
- BCAB 11-05-2024
- Dividend Yield
- STEM N/A
- BCAB N/A
- EPS Growth
- STEM N/A
- BCAB N/A
- EPS
- STEM N/A
- BCAB N/A
- Revenue
- STEM $360,632,000.00
- BCAB N/A
- Revenue This Year
- STEM N/A
- BCAB N/A
- Revenue Next Year
- STEM $131.69
- BCAB N/A
- P/E Ratio
- STEM N/A
- BCAB N/A
- Revenue Growth
- STEM N/A
- BCAB N/A
- 52 Week Low
- STEM $0.30
- BCAB $1.14
- 52 Week High
- STEM $4.30
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- STEM 58.50
- BCAB 47.87
- Support Level
- STEM $0.31
- BCAB $1.86
- Resistance Level
- STEM $0.67
- BCAB $2.40
- Average True Range (ATR)
- STEM 0.07
- BCAB 0.25
- MACD
- STEM 0.03
- BCAB -0.01
- Stochastic Oscillator
- STEM 73.36
- BCAB 30.38
About STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on innovative technology services that transform the way energy is distributed and consumed.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.